<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209180</url>
  </required_header>
  <id_info>
    <org_study_id>CVDSR</org_study_id>
    <nct_id>NCT03209180</nct_id>
  </id_info>
  <brief_title>Immediate Release Versus Slow Release Carvedilol in Heart Failure</brief_title>
  <acronym>SLOW-HF</acronym>
  <official_title>Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of clinical effect and treatment quality of immediate release carvedilol (IR)&#xD;
      versus slow release carvedilol (SR) in patients with HFrEF&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SLOW-HF trial is a phase 4, randomized, open label, multicenter study to evaluate the&#xD;
      therapeutic efficacy of carvedilol-SR compared to carvedilol-IR in patients with heart&#xD;
      failure with reduced ejection fraction. Patients with stable HFrEF will be randomly assigned&#xD;
      (1:1) to carvedilol SR group (160 patients) and carvedilol IR group (160 patients).&#xD;
&#xD;
      After randomization, patients will be followed for 6 months. The primary endpoint is the&#xD;
      change in NT-proBNP level from baseline to the study end. The secondary endpoints include the&#xD;
      frequency of NT-proBNP increment &gt;10% from baseline, composite of all-cause mortality and&#xD;
      readmission, mortality rate, readmission rate, changes in blood pressure, quality of life,&#xD;
      and drug compliance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>PROBE and NON-INFERIORITY DESIGN for Slow Release CarVeDilol-SR to Rapid Release Carvedilol-IR</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>6 months</time_frame>
    <description>Change of NT-proBNP from baseline to 6 months after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in all-cause deaths between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in hospitalization for heart failure between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in blood pressure change between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>6 months</time_frame>
    <description>Differences in dyspnea measured with visual analogue scale between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Differences in drug compliance measured with 'pill-count' between the groups during clinical follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Carvedilol IR (Immediate Release)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CarVeDilol-SR (Slow Release)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CarVeDilol-SR (Slow Release)</intervention_name>
    <description>patients will receive slow-release carvedilol (SR) once daily</description>
    <arm_group_label>CarVeDilol-SR (Slow Release)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol IR (Immediate Release)</intervention_name>
    <description>patients will receive immediate release carvedilol (IR) twice daily</description>
    <arm_group_label>Carvedilol IR (Immediate Release)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. At least or more than 20-years-old male and female&#xD;
&#xD;
          2. Confirmed left ventricular ejection fraction ≤40% by echocardiography within&#xD;
             pre-analytical 6 months&#xD;
&#xD;
          3. NT-proBNP level ≥ 125 pg/ml or BNP level ≥ 35 pg/ml within pre-analytical 3 months&#xD;
&#xD;
          4. Clinically stable patient without evidence of congestion or extracellular fluid&#xD;
             retention; those could be candidate of β-blockers&#xD;
&#xD;
          5. Patients providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systolic blood pressure at sitting position &lt; 90mmHg or resting heart rate &lt; 50 /min&#xD;
             at screening&#xD;
&#xD;
          2. Patient has a contraindication to β-blockers&#xD;
&#xD;
          3. Patient who are expected to take another β-blocker after randomization&#xD;
&#xD;
          4. Cardiovascular diseases&#xD;
&#xD;
               -  Ischemic heart disease (unstable angina, myocardial infarction) within 1 month&#xD;
&#xD;
               -  Hypertrophic cardiomyopathy&#xD;
&#xD;
               -  Cor pulmonale&#xD;
&#xD;
               -  Hemodynamically significant stenosis of aorta, aortic valve, or mitral valve&#xD;
&#xD;
               -  any acute myocardial infarction with complication&#xD;
&#xD;
          5. Severe cerebrovascular accident (for example, ischemic stroke or cerebral hemorrhage)&#xD;
             pre-analytical within 6 months&#xD;
&#xD;
          6. Glottis edema, allergic rhinitis, respiratory diseases with bronchospasm such as&#xD;
             asthma and chronic obstructive lung disease&#xD;
&#xD;
          7. Peripheral vascular disease (for example, Raynaud syndrome, intermittent claudication)&#xD;
&#xD;
          8. Patients who need vasopressor due to prominent volume retention/overload&#xD;
&#xD;
          9. Moderate to Severe retinopathy (for example, retinal hemorrhage, visual disturbance,&#xD;
             retinal microaneurysm within 6 months)&#xD;
&#xD;
         10. Impaired renal function (Serum creatinine ≥ 2.5 mg/dL) or hepatic function (AST or ALT&#xD;
             ≥ 3 x ULM)&#xD;
&#xD;
         11. Patients in clinical status that can significantly influence on absorption,&#xD;
             distribution, metabolism, and secretion of drugs for clinical trial&#xD;
&#xD;
               -  history of major gastrointestinal surgery, such as gastrectomy or gastric bypass&#xD;
                  surgery&#xD;
&#xD;
               -  inflammatory bowel disease within 12 months&#xD;
&#xD;
               -  current gastric ulcer, pancreatic function abnormality including pancreatitis,&#xD;
                  gastrointestinal/rectal bleeding which demand treatment&#xD;
&#xD;
               -  current urologic stenosis or obstruction which demand treatment&#xD;
&#xD;
         12. Confirmed or suspected drug/alcohol abuse within 6 months&#xD;
&#xD;
         13. Pregnant or lactating women, suspected pregnant women or lactating women&#xD;
&#xD;
         14. Chronic inflammatory diseases which demand anti-inflammatory treatment&#xD;
&#xD;
         15. Hypersensitivity to carvedilol&#xD;
&#xD;
         16. Malignant disease including lymphoma and leukemia within 5 years&#xD;
&#xD;
         17. Patients who were prescribed other medication for any clinical trials pre-analytical&#xD;
             within 28 days&#xD;
&#xD;
         18. Patients who are predicted to have prolonged hospital days due to other medical&#xD;
             problems other than chronic heart failure (for example, femur neck fracture)&#xD;
&#xD;
         19. Patients who are considered as inappropriate to participate in the clinical trial by&#xD;
             testers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sejong Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Bucheon</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk-keun Hong, MD</last_name>
      <phone>82-10-8947-5309</phone>
      <email>hongsk11@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangdong</state>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae-gyun Park, MD</last_name>
      <phone>82-2-2224-2379</phone>
      <email>dgpark@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea Univ. Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eung-joo Kim, MD,PhD</last_name>
      <phone>82-8-2626-3022</phone>
      <email>withnoel@empas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Il-won</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-Seok Jeon, MD,PhD</last_name>
      <phone>82-2-3410-3448</phone>
      <email>esjeon1107@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Jungnang</state>
        <zip>02053</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-Yeon Kim, MD</last_name>
      <phone>82-2-2276-7095</phone>
      <email>ks7688@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea Univ. Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seongbuk</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun-jun Hong, MD,PhD</last_name>
      <phone>82-2-920-5445</phone>
      <email>psyche94@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Joong Kim, MD,PhD</last_name>
      <phone>82-2-3010-3154</phone>
      <email>jjkim@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou Univ. Medical Center</name>
      <address>
        <city>Suwon-si</city>
        <state>Yeong-tong</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun-han Shin, MD,PhD</last_name>
      <phone>82-31-219-5710</phone>
      <email>shinjh@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Ju Choi, MD, PhD</last_name>
      <phone>82-31-787-7007</phone>
      <email>djchoi@snubh.org</email>
    </contact>
    <contact_backup>
      <last_name>Jin Joo Park, MD</last_name>
      <phone>82-31-787</phone>
      <phone_ext>7074</phone_ext>
      <email>jinjooparkmd@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-Min Kang, MD,PhD</last_name>
      <phone>82-2-2273-3339</phone>
      <email>smkang@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Metropolitan Government Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-a Kim</last_name>
      <phone>82-2-870-2213</phone>
      <email>kma@brmh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hae-Young Lee, MD,Ph D</last_name>
      <phone>82-2-2072-4875</phone>
      <email>hylee612@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Su Yoo, MD,PhD</last_name>
      <phone>82-33-741-0908</phone>
      <email>yubs@yonsei.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>HFrEF</keyword>
  <keyword>Carvedilol</keyword>
  <keyword>Slow Release</keyword>
  <keyword>NT-proBNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

